ClinicalTrials.gg
RecruitingNCT07149610RCT_SMUpdated Aug 18, 2026

Connected Care for Type 2 Diabetes Self-Management

An interventional study of M-health solution classified as Class I Medical Devices, equipped with a CE certificate. The m-health solution will be integrated with the EPR currently used by the CADs of the Marche region in Diabetes Type 2, sponsored by Marche Region Regional Health Agency. Recruiting at 11 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Marche Region Regional Health Agency · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
388
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 421 studies in Diabetes Mellitus, Type 2 with a site in Italy — 45 open to participants now, 61 under way, 12 of them phase 3. Diabetes Mellitus, Type 2 · Italy.

Planned enrollment
148th of 321
388 · median 320
Started
2025
with 12 others
No phase
71 of 421
14 open now
Primary completion
2026-11
later than 27 of 60 live
Registered
393rd of 421
by date

Among the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy, this one is the 148th largest by planned enrollment of the 321 interventional ones that give a count, is one of 13 that started in 2025, is one of 71 with no phase, reaches primary completion later than 27 of the 60 other live ones, and was the 393rd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

45 of the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy are open now. Recruiting first, the newest first:

39 more — sign in →

All 45 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 421 studies in Diabetes Mellitus, Type 2 with a site in Italy, or all of them as a file.
02

Study summary

The primary objective of this Randomized Clinical Trial is to improve the self-management (SM) competencies of patients affected by Type 2 Diabetes Mellitus (T2DM) living in the Marche region (Italy) through the support of a mobile health (m-health) solution personalised by the diabetologist and integrated with the Electronic Patient Record (EPR), assessed through the change in glycated haemoglobin (HbA1c) levels (%) from baseline to the end of the intervention (primary outcome).

Researchers will compare the use of the m-health solution (treated group) to usual T2DM care (control group) in determining change in HbA1c levels (%). The intervention will start at the Diabetic Centres (CADs) where patients are currently followed up and will then take place in each participant's home

Participants of the treated group will:

  • receive dedicated training on the use of the m-health solution
  • receive the personalization of the m-health solution
  • use the m-health solution to: 1) track and view the data related to their health status (e.g., glycaemic status, lifestyle habits, diet) and treatment plane; 2) receive alerts and motivational messages; communicate with the Health Care Professionals (HCPs) of the Diabetic Centre (CAD) in case of need; 3) access to the educational material and to the technical assistance, when needed.

HCPs will be able to monitor the patients' data and clinical parameters and to communicate with the patients. After a baseline evaluation (T0), three follow-up evaluations will be conducted at 4, 8 and 12 months (T1-T2-T3 respectively) , during the usual physician' visits, as part of clinical routine.

The evaluation phases (T0, T1, T2, T3) will be conducted through data derived from: 1) self-administered and paper-based questionnaires, validated in the Italian language; 2) the clinical assessment of patients; 3) the m-health solution, as data automatically derived from the m-health solution; 4) a focus group carried out in a subsample of participants.

Data regarding different health-related areas (T2DM severity; medication adherence; lifestyle habits; self-efficacy related to management of the disease; quality of life), usability of the m-health solution, participants' experience with the intervention, utilization of the m-health solution by the patients, and the cost-effectiveness of the intervention, will be evaluated.

Patients participating in the study will not be required to make any additional visits or undergo any laboratory analysis beyond those specified in their therapeutic plan.

Read the detailed description

1. Details about recruitment: Prior to the start of the study, the medical directors, the nursing healthcare managers, and nursing coordinators of the CADs involved in the study will be informed about characteristics, methods and aims of the research. The principal investigator (PI) of the study will be responsible to conduct a specific training session on the protocol, the procedures and the data collection to all the HCPs of the CADs participating in the study as staff (e.g., doctors, dietician, nurses), to ensure standardised procedures across all the participating centres and without interfering with clinical-assistance and other priority activities. At the same time, the owners of the mhealth solution will provide specific training on the use of m-health solution, including the interface integrated with the EPR and the mobile app for the patients. In details, the company contact person, in collaboration with the scientific coordinator of the company, will held an in-presence training session of 1 hour for the HCPs, in a dedicated time before the start of the study, to be conducted in small groups, in an interactive way, accepting and answering any doubts. This educational session will include a theorical component, regarding characteristics, functionalities and potentialities of the m-health solution, and a practical component, based on simulations about the use of the m-health solution and about an example of training that will be provided to the participants. The necessity to strengthen and/or supplement the training will be evaluated by the owners of the m-health solution, and, eventually, faced.

The information letter and the paper-based consent form will be delivered by the investigators to the eligible patients, in the CADs of the Marche Region involved in the study, making themselves available for clarifications and explanations. The participants will be enrolled only after having been deeply informed about modalities and principles of data treatment, along with the aims and the characteristics of the study, and only after signing the paper-based informed consent form for the authorization of data processing and for voluntary participation in the study, after a reflection period of 2 weeks. The participants having signed the informed consent to participate in the research will be invited by the investigators, through telephonic calls and/or emails, to consult one of the diabetologist participating as staff in the study. The doctors will carry out the visits to attest the eligibility of the participant for the study, with the support of other HCPs of the CADs, such as nurses, based on the inclusion criteria. The doctor will sign the consent forms too, making him-/her-self available to provide further details and to solve any doubts of the patients. Each signature will be personally dated by each signatory, and the informed consent and any additional patient information will be retained by the investigator. A signed copy of the informed consent and information sheet will be given to each patient. Participants who have signed the consent form but whose inclusion criteria are not confirmed by the doctor will not be included in the study.

2- Legal, ethical and technical considerations:

This study, and, consequently, the data collection, usage and storage procedures, will be conducted according to the principles expressed in:

  • The Declaration of Helsinki 2024
  • the standards of Good Clinical Practice
  • the Legislative Decree no. 196/03 Italian Personal Data Protection Code
  • EU General Data Protection Regulation 2016
  • Legislative Decree No. 101/2018 on Provisions for the adaptation of national legislation to the provisions of European Regulation 2016/679
  • Guidelines for the collection of informed consent for participation in clinical trials, National Coordination Centre for Ethics Committees.

The study will start only after notification and acknowledgement by the Regional Ethics Committee and the completion of the administrative requirements of the institution where the study is being conducted. No sponsorship is envisaged for the conduction of this study

03

Conditions studied

  • Diabetes Type 2

Keywords

  • self-management
  • digital solution
  • Diabete type 2
  • Chronic diseases
  • glycated hemoglobin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with T2DM (as confirmed by the physician's diagnosis);
  • belonging to one of the 13 Diabetes Centres (CADs) of the Marche region in Italy (Pesaro, Urbino, Fano, Senigallia, Jesi, Fabriano, IRCCS-INRCA, Azienda Ospedaliera Universitaria delle Marche, Civitanova Marche, Macerata, Fermo, San Benedetto del Tronto e Ascoli Piceno);
  • age > = 18;
  • resident in the Marche region;
  • > 7 on most recent laboratory report within the last 3 months;
  • no changes in diabetes medication in the previous 6 months;
  • no prescription for any hypoglycaemic agent within the previous 4 weeks or taking a consistent dose of one or more oral hypoglycaemic agents for more than 12 weeks;
  • owning smartphone/mobile phone with an internet connection;
  • capable to consent;
  • fulfilling and signing the ;
  • with self-reported competencies of communicating verbally in local language (corresponding to a level of Italian language knowledge =>A2 of the CEFR levels).

Exclusion criteria

Exclusion Criteria:

  • acute medical problems: myocardial infarction or stroke within 6 months, difficulty in exercise and physical activity due to spinal disease (intervertebral disc prolapse, spinal stenosis, etc.), joint disease, or major surgery at the time of screening, painful arthritis, spinal stenosis, amputation, painful foot lesions or neuropathy limiting balance and mobility, advanced Parkinson's disease and/or neuromuscular disorders, advanced dementia, cancer, in long-term therapy, significant visual or hearing impairment, uncontrolled hypertension or other serious conditions that restrict their participation in the study, severe/major depression and other relevant psychiatric disorders;
  • estimated \< 30 mL/min/1.73 m2;
  • plan to receive surgery that could limit physical activity during the study period;
  • pregnant or breastfeeding;
  • participation in another studies;
  • lack of written .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
388 participants (estimated)

Study arms

  • Active comparator
    Treated group (utilizing m-health solution)

    The participants assigned to the treated group, in addition to the regular T2DM care, will be provided with a m-health solution to support the SM of T2DM, aimed to improve their SM' skills and abilities. The m-health solution will allow the patients to: 1. track their data, such as glycaemic status, blood pressure, therapy, steps and physical activity, sleep, body weight, laboratory tests (HbA1c, creatinine, cholesterol, etc.); 2. check the target values defined by the diabetologist (e.g., blood glucose, HbA1c, lipid profile, etc.); 3. view their treatment plan; 4. view the diet indicated by the dietitian and record meals/calculate calories/carbohydrates in a simple way (e.g., through list of foods with pictures of dishes and portions); 3\) receive alerts (e.g., therapy reminders) and motivational messages; 4) view summary statistics; 5) communicate with the HCPs through a chat; 6) fill out surveys; 7) access to educational material and technical assistance;

    Device: M-health solution classified as Class I Medical Devices, equipped with a CE certificate. The m-health solution will be integrated with the EPR currently used by the CADs of the Marche region

  • No intervention
    Control group (attending usual T2DM care)

    The patients assigned to the control group will receive regular T2DM care according to the Diabetes Association standards

Interventions

  • DeviceM-health solution classified as Class I Medical Devices, equipped with a CE certificate. The m-health solution will be integrated with the EPR currently used by the CADs of the Marche region

    The m-health solution used in the study includes the following interfaces: 1. for the HCPs of the CADs: * a section of the EPR currently used (Metaclinic), to set the mobile application and to collect clinical data recorded by the patients; * a software to develop and monitor personalised diets (MetaDieta); 2. for the patients: two mobile applications, one for the monitoring of the clinical data and life style (DiaWatch Meteda) and one for the monitoring of the diet (MyDiet), with the latter accessible from a 'button' included in the first one. The HCPs of the CADs, already having access to the EPR Metaclinic, will access a dedicated section for the setting of the target values and goals (e.g., glycaemia, physical activity, etc.) and for the activation of the app DiaWatch Meteda. After the connection of the app with Metaclinic, the data registered in the apps by the patients will be visible by the HCPs in the EPR dashboard.

06

What researchers measure

Primary outcomes

  1. To improve the SM competencies of patients affected by T2DM living in the Marche region through the support of a m-health solution personalized by the diabetologist and integrated with the EPR of patients.

    This outcome will be assessed through the change in HbA1c levels (%)

    Time frame: This outcome will be evaluated from baseline to the end of treatment, in details, at month 0, at month 4, at month 8 and at month 12.

Secondary outcomes

  1. To evaluate the changes, after the intervention, in T2DM severity, through clinical records/physician visits.

    This outcome will be assessed evaluating the change in the level of fasting glucose (mg/dl)

    Time frame: This outcome will be evaluated from baseline to the end of treatment, in details, at month 0, at month 4, at month 8 and at month 12.

  2. To evaluate the changes, after the intervention, in T2DM severity, through clinical records/physician visits.

    This outcome will be assessed evaluating the change in glycaemic variability/capillary blood glucose monitoring, when foreseen by patients' therapeutic plan

    Time frame: This outcome will be evaluated from baseline to the end of treatment, in details, at month 0, at month 4, at month 8 and at month 12.

  3. To evaluate the changes, after the intervention, in T2DM severity, through clinical records/physician visits.

    This outcome will be assessed evaluating the change in the levels of Serum total cholesterol (mg/dl), triglycerides (mg/dl), High-Density Lipoproteins (mg/dl) and Low-Density Lipoproteins cholesterol (mg/dl).

    Time frame: This outcome will be evaluated from baseline to the end of treatment, in details, at month 0, at month 4, at month 8 and at month 12.

  4. To evaluate the changes, after the intervention, in T2DM severity, through clinical records/physician visits.

    This outcome will be assessed evaluating the change in Microalbuminuria levels (mg/dl).

    Time frame: This outcome will be evaluated from baseline to the end of treatment, in details, at month 0, at month 4, at month 8, and at month 12.

  5. To evaluate the changes, after the intervention, in T2DM severity, through clinical records/physician visits.

    This outcome will be assessed evaluating the change in waist circumference (cm)

    Time frame: This outcome will be evaluated from baseline to the end of treatment, in details, at month 0, at month 4, at month 8 and at month 12.

  6. To evaluate the changes, after the intervention, in T2DM severity, through clinical records/physician visits.

    This outcome will be assessed through evaluating the body weight (kg).

    Time frame: This outcome will be evaluated from baseline to the end of treatment, in details, at month 0, at month 4, at month 8 and at month 12.

  7. To evaluate the changes, after the intervention, in T2DM severity, through clinical records/physician visits.

    This outcome will be assessed evaluating the change Body Mass Index (BMI) (kg/m\^2).

    Time frame: This outcome will be evaluated from baseline to the end of treatment, in details, at month 0, at month 4, at month 8 and at month 12.

  8. To evaluate the changes, after the intervention, in T2DM severity, through clinical records/physician visits.

    This outcome will be assessed evaluating the change in blood pressure's values (mmHg);

    Time frame: This outcome will be evaluated from baseline to the end of treatment, in details, at month 0, at month 4, at month 8 and at month 12.

  9. To evaluate the changes, after the intervention, in T2DM severity, through clinical records/physician visits.

    This outcome will be assessed evaluating changes regarding the following anamnestic measurements: comorbidities, medications and complications related to T2DM, including the number of hypoglycaemia and hyperglycaemia episodes in the last 4 months.

    Time frame: This outcome will be evaluated from baseline to the end of treatment, in details, at month 0, at month 4, at month 8 and at month 12.

  10. To evaluate the changes, after the intervention, in T2DM severity, through clinical records/physician visits.

    This outcome will be assessed evaluating the number of unscheduled hospital visits due to hypoglycaemia or hyperglycaemia within 12 months: outcome assessed retrospectively through the Administrative Healthcare Databases (HADs) of Hospital discharge records occurred in public and private hospitals and Emergency and Urgency care according to ICD-9 codes (250.3, 250.8, 251.0, 251.1, 251.2, 270.3, 790.6).

    Time frame: This outcome will be evaluated from HADs, at baseline (month 0) and at the the end of treatment (namely at month 12).

  11. To evaluate the changes, after the intervention, in the levels of medication adherence

    This outcome will be assessed through the "Medication Adherence Report Scale- MARS-5 ©", validated in Italy, composed by five questions on both unintentional and intentional non-adherence, namely forgetting, changing dosage, stopping, skipping and taking less medication. The score ranges from 5 to 25, where a higher score indicates higher self-reported adherence.

    Time frame: This outcome will be evaluated from baseline to the end of treatment, in details, at month 0, at month 4, at month 8 and at month 12.

  12. To evaluate the changes, after the intervention, in dietary and alcohol consumption habits

    This outcome will be assessed through the questionnaire "Literature Based Adherence Score to Mediterranean Diet- MEDILITE", that enables the user to ascertain their consumption of 9 food categories, defined in scientific studies examining the correlation between adherence to the Mediterranean diet and health outcomes. The 9 food groups are: fruits; vegetables; cereals; legumes; fish; meat and meat products; dairy products; alcohol; olive oil. The scores assigned differ for each item: typical foods of the Mediterranean diet (2=highest consumption category; 1=intermediate category; 0=lowest category); non-typical foods (2=lowest intake; 1=intermediate intake; 0=highest consumption); alcohol (2=1-2 alcohol units/day; 1=1 alcohol unit/day; 0= \>2 alcohol units/day); olive oil (2=regular use; 1=frequent use; 0=occasional use). The final score, obtained from the sum of all these scores, ranges from 0 (low adherence to the Mediterranean diet) to 18 (high adherence).

    Time frame: This outcome will be evaluated from baseline to the end of treatment, in details, at month 0, at month 4, at month 8 and at month 12.

  13. To evaluate the changes, after the intervention, in smoking habits

    This outcome will be assessed through n. 11 ad hoc questions to analyse the smoking habits and history, elaborated from the questions included in the EPR of patients (routinely collected) and from the National Institute of Statistics-ISTAT questionnaires.

    Time frame: This outcome will be evaluated from baseline to the end of treatment, in details, at month 0, at month 4, at month 8 and at month 12.

  14. To evaluate the changes, after the intervention, in levels of physical activity

    This outcome will be assessed through the "International Physical Activity Questionnaire- Short Form- IPAQ-SF": validated in Italian language, evaluates frequency (days per week) and duration (minutes per day) of three types of activity, i.e., walking, moderate intensity and vigorous intensity activities. The scale assigns a score to each activity and a total score, calculated from the duration and frequency of three activities. Activity volume can also be expressed in MET-minutes (METs x minutes x frequency per week). Scores can be continuous or categorized: 1. Low - below moderate or high criteria; 2. Moderate - e.g., 3+ days of vigorous activity (20+ min/day), or 5+ days of moderate/walking (30+ min/day), or 600+ MET-min/week; 3. High - 3+ days vigorous activity totaling 1500+ MET-min/week, or 7+ days of mixed activity reaching 3000+ MET-min/week.

    Time frame: This outcome will be evaluated from baseline to the end of treatment, in details, at month 0, at month 4, at month 8 and at month 12.

  15. To evaluate the changes, after the intervention, in the levels of self-efficacy perceived by partecipants

    This outcome will be assessed through the "The Italian Diabetes Management Self-Efficacy Scale- IT-DMSES", that consists of 15 items divided into two factors of self-efficacy in diabetes management: 1) self-perception of patient's ability to manage the activities related to diabetes management (e.g., medication adherence, Glycaemic Control), and 2) self-efficacy in lifestyle management (e.g., eating behaviours, physical activities). Scores per factor range from 0 to 10, indicating low (0-3), mid (4-6), and high (7-10) levels of self-efficacy.

    Time frame: This outcome will be evaluated from baseline to the end of treatment, in details, at month 0, at month 4, at month 8 and at month 12.

  16. To evaluate the changes, after the intervention, in the levels of quality of life perceived by partecipants

    This outcome will be assessed through the scale "EuroQol 5-digit 5-level Visual Analogue Scale- EQ-5D-5L VAS", validated in Italian language, in details through its descriptive system, consisting on five dimensions: mobility, independence, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no/mild/moderate/severe/extreme problems. The participant is asked to indicate his/her health status with the most appropriate statement in each of the five dimensions, producing also a 5-digit number that describes the health profile of the participant.

    Time frame: This outcome will be evaluated from baseline to the end of treatment, in details, at month 0, at month 4, at month 8 and at month 12.

  17. To evaluate the changes, after the intervention, in the levels of quality of life perceived by partecipants

    This outcome will be assessed through the scale "EuroQol 5-digit 5-level Visual Analogue Scale- EQ-5D-5L VAS", validated in Italian language, in details through the EQ VAS part, represented in a vertical scale from 0 to 100 in 5-point increments. The participant is asked to represent his/her health status putting a cross on the scale, then translated into an integer between 0 and 100.

    Time frame: This outcome will be evaluated from baseline to the end of treatment, in details, at month 0, at month 4, at month 8 and at month 12.

  18. To collect information regarding participants' perception of usability of the m-health solution, their level of satisfaction and any benefits they have experienced.

    This outcome will be through the Italian version of the System Usability Scale-SUS" , a ten-item tool giving a global view of subjective assessments of usability. The response options are based on the Likert scale, from 1= strong disagreement; to 5= strong agreement, for a total score ranging from 0 to 100, to be evaluated based on a computation table.

    Time frame: This outcome will be evaluated at month 4, at month 8 and at the end of the intervention (namely at month 12).

  19. To collect information regarding participants' experience with the intervention.

    This outcome will be assessed through focus groupm carried out in a subsample of participants (max 5-10 participants for each focus group) to gain additional insights on the patient's experience with the intervention, that will allow patients to discuss about perceptions and opinions about the utility of the intervention and of the m-health solution, letting patients free to express their ideas and suggestions. The focus group will be carried out by two experienced researchers from the research team: 1) the moderator, acting as initiator and facilitator of the discussion, as well as mediating between participants and conducting discussion through posing main questions; 2) the observer/note-taker, acting as rapporteur, writing down notes about both discussion between participants (e.g., topics covered, opinions emerging, contrasts, new issues). The discussion will be audio recorded and transcribed verbatim to facilitate subsequent analysis and reporting.

    Time frame: This outcome will be evaluated at the end of the intervention, namely at month 12

  20. To collect information regarding the utilization of the m-health solution by the patients

    This outcome will assessed through data analytics collected by the digital system as utilization measures automatically derived from the mobile apps used by the patients, namely, number of accesses, time of use, and frequency of use of the key features such as inputs of data, access to training/information documents, chat, and consultation of target values and treatment plan. The data collected will be processed to produce periodic reports highlighting areas of increased use, any critical issues, and suggestions for future improvements.

    Time frame: This outcome will be evaluated at month 4, at month 8 and at the end of treatment, namely at month 12

  21. To evaluate the cost-effectiveness of the intervention.

    This outcome will be assessed through Incremental Cost-Effectiveness Ratio (ICER), that will be calculated as the difference in costs divided by the difference in health benefits over an 18-month period from a healthcare sector perspective. A bottom-up micro-costing approach will assess all individual-level costs for control and intervention groups, including diabetes care (hospital admissions, emergency care, outpatient visits, lab tests, drugs, consumables). The intervention group also includes technology-related costs (software, maintenance). The evaluation is within-trial. Cost-effectiveness is based on HbA1c; QALYs, derived from EQ-5D-5L, are used for cost-utility analysis. ICERs will be reported with 95% confidence intervals via bootstrapping. A €25,000-€60,000 per QALY threshold and sensitivity analyses with acceptability curves will assess uncertainty.

    Time frame: This outcome will be evaluated at the end of the intervention, namely at 12 months

07

Study locations

9 of 11 sites recruiting
  • Diabetic Center of Azienda Ospedaliero Universitaria delle Marche
    Ancona, Ancona 60126, Italy
    Recruiting
  • Diabetic Center of National Institute for the Care and Treatment of the Elderly (Istituto Nazionale di Ricovero e Cura per Anziani-INRCA)
    Ancona, Ancona 60127, Italy
    Recruiting
  • Diabetic Center of Territorial Healthcare Authority of Ancona province
    Fabriano, Ancona 60044, Italy
    Not yet recruiting
  • Diabetic Center of Territorial Healthcare Authority of Ancona province
    Iesi, Ancona 60035, Italy
    Recruiting
  • Diabetic Center of Territorial Healthcare Authority of Ascoli Piceno province
    Ascoli Piceno, Ascoli Piceno 63100, Italy
    Not yet recruiting
  • Diabetic Center of Territorial Healthcare Authority of Ascoli Piceno province
    San Benedetto del Tronto, Ascoli Piceno 63074, Italy
    Recruiting
  • Diabetic Center of Territorial Healthcare Authority of Fermo province
    Fermo, Fermo 63900, Italy
    Recruiting
  • Diabetic Center of Territorial Healthcare Authority of Macerata province
    Civitanova Marche, Macerata 62012, Italy
    Recruiting
  • Diabetic Center of Territorial Healthcare Authority of Macerata province
    Province of Macerata, Macerata 62100, Italy
    Recruiting
  • Diabetic Center of Territorial Healthcare Authority of Pesaro Urbino province
    Fano, Pesaro-Urbino 61032, Italy
    Recruiting
  • Diabetic Center of Territorial Healthcare Authority of Pesaro Urbino province
    Pesaro, Pesaro-urbino 61122, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Nov 2026, 13 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 13 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Sep 2, 2025
StartActual
Oct 13, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07149610
Lead sponsor
Marche Region Regional Health Agency
Responsible party
Sponsor
First posted
Sep 2, 2025
Start date
Oct 13, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 18, 2026

Study contacts

Project Manager
Contact
roberta.papa@regione.marche.it
+39 071. 8064137

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion